NASH Treatment Pipeline: What Actually Works in 2025
New NASH therapies show promise, but the bar for liver histology improvement remains high. Here's what's working in trials.
Published May 23, 2026·4 min read·Evidence: Peer Reviewed
What They Found
This review examines the current therapeutic landscape for NASH (now called MASLD), including recently approved treatments and promising pipeline candidates. The authors synthesize data from multiple clinical trials to assess which interventions are actually moving the needle on liver histology and fibrosis.
Why It Matters
NASH affects 3-5% of the global population and is the fastest-growing indication for liver transplant. For years, we've had lifestyle interventions and off-label use of diabetes drugs, but no FDA-approved NASH-specific therapies.
The game-changer has been GLP-1 receptor agonists. Semaglutide trials show 30-40% of patients achieving ≥2-point NASH resolution without worsening fibrosis. The mechanism is multifactorial: direct hepatic effects reducing lipogenesis, systemic insulin sensitization, and meaningful weight loss (10-15% body weight).
Pipeline candidates targeting specific pathways are showing promise. FGF21 analogs improve hepatic steatosis through enhanced fatty acid oxidation. PPAR agonists like elafibranor target inflammation and fibrosis directly. Thyroid hormone receptor-β agonists (resmetirom) recently showed efficacy in reducing liver fat and improving NASH histology in phase 3 trials.
The critical endpoint remains histologic improvement. Many compounds reduce liver enzymes or imaging-based steatosis measures, but reversing fibrosis and achieving NASH resolution requires sustained intervention targeting multiple pathways simultaneously.
What I'd Watch For
Most trials are 12-18 months, which may not capture long-term safety or durability of response. Liver biopsy remains the gold standard, but it's invasive and sampling-dependent. New non-invasive biomarkers and imaging techniques need validation against histologic outcomes.
The patient populations in these trials often exclude the sickest patients with advanced fibrosis or cirrhosis. Real-world effectiveness may differ significantly from controlled trial settings. Cost and access will be major barriers—GLP-1 agonists cost $1,000+ monthly.
Bottom Line
GLP-1 agonists are the current best option for NASH patients who also have diabetes or obesity. For non-diabetic NASH, combination therapy targeting multiple pathways will likely be necessary. Don't wait for perfect data—aggressive lifestyle intervention plus metformin remains first-line for most patients.